About
The AAT gene is extremely polymorphic. In addition to the wildtype allele M, there are more than 100 variants. The S and Z alleles account for most of the mutations with the Z mutation being the more severe in patients with AAT deficiency. Individuals with MZ and MS are considered as carriers and appear to not be at increased risk for lung and liver disease while individuals with ZZ or SZ are considered as AAT deficient with moderate to severe deficiency.
Diagnosis
On one hand, AAT-Deficiency Pulmonary Symptoms often appear after 40 years old, whereas the AAT-Deficiency Hepatic Symptoms may be manifested in early childhood. On the other hand, disease progression can be slowed down by early therapy and by minimizing exposure to aggravating agents. That is why it is crucial to identify people susceptible to AAT deficiency-related pulmonary and hepatic damage and enrol them in AAT Deficiency management care as soon as possible.
Although guidelines recommend that everyone with COPD, Chronic Obstructive Pulmonary disease, or unexplained bronchiectasis be tested for Alpha-1, 90% of individuals remain undiagnosed with severe Alpha-1 and diagnosis occurs several years after the onset of symptoms.
Different methods can be used to detect AAT deficiency. The most common is by protein phenotyping using isoelectrofocusing (IEF). AAT can be directly measured by nephelometry or immunoturbidimetry, but this measurement can be sometimes misleading because AAT concentrations can be increased and/or decreased due to conditions unrelated to AAT deficiency. Genotyping assays are also available for the most common deficiency-associated alleles such as S and Z, but these assays can miss significant numbers of at-risk people with other alleles.
Sebia's expertise
Our HYDRAGEL 18 A1AT ISOFOCUSING kit is designed for the qualitative detection and identification of the different phenotypes of alpha-1 antitrypsin by isoelectrofocalisation. The semi-automated HYDRASYS 2 SCAN FOCUSING system performs all the steps needed to obtain gels ready for interpretation.
Featured resources on Alpha-1 Antitrypsin Deficiency
See all resourcesPitfalls and ceveats of A1AT diagnosis
Pitfalls and caveats in α1-antitrypsin deficiency testing: a guide for clinicians.
Evaluation of Sebia’s isoelectrofocusing kit for A1AT
Evaluation of Sebia’s isoelectrofocusing kit for A1AT with HYDRASYS.
The importance of SPE and A1AT phenotyping for a better AATD patient management
Educational Webinar Pr Simone Scarlata
The importance of SPE and A1AT phenotyping for a better AATD patient management
Educational Webinar Pr Simone Scarlata
Improving the diagnosis of AATD with aid of Serum Protein Electrophoresis
Educational Webinar with Dr. Ilaria Ferrarotti
HYDRASYS 2 SCAN FOCUSING: Overview
Learn more about the HYDRASYS 2 SCAN FOCUSING for a fast and user-friendly gel electrophoresis processing.
Upcoming events
See all eventsApr. 11, 2022 Nov. 21, 2024
IFCC Euromedlab 2021
Sebia booth: #121
Sebia Workshop: EduW22
Jun. 27, 2022 Jun. 29, 2022
IFCC Worldlab 2022
Sebia booth: #72
Sebia Workshop: EduW25
Alpha 1-Antitrypsin (A1AT) Phenotype Testing
The gold standard assay for the alpha 1-antitrypsin (A1AT) phenotype testing.
- Diagnosis of alpha-1 antitrypsin deficiency: Modalities, indications and diagnosis strategy, M.Balduyck et al, revues des maladies respiratoires, 2014, ; 31,729-745
- Efficacy of the Detection of the α1-Antitrypsin “Z” Deficiency Variant by Routine Serum Protein Electrophoresis, Patricia Slev et al, Am J Clin Pathol 2008; 130:568-572
- Pitfalls and caveats in α1-antitrypsin deficiency testing: a guide for clinicians, Frabciosi et al. The lancet.com/respiratory Vol 7 December 2019
This section contains information intended for wide distribution and may therefore contain product details or information that is not available or valid in your country.
Please contact your local Sebia representative. Information intended for healthcare professionals.
Carefully read the instructions in the reagent package inserts and instrument manuals.